Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.
Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.
The GelrinC® implant is based on a degradable hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. Unlike traditional microfracture, which often results in fibrocartilage with inferior biomechanical properties, GelrinC® aims to regenerate near-native hyaline cartilage. The off-the-shelf nature of the product eliminates the need for cell harvesting and culturing, simplifying the surgical procedure and potentially reducing costs and recovery time.
The significance of this advancement lies in the large unmet need in knee cartilage repair. Current treatment options include microfracture, which has limited durability, and cell-based therapies like autologous chondrocyte implantation (ACI) that require two surgeries and weeks of cell culture. An off-the-shelf, single-step solution could transform the treatment paradigm, offering improved outcomes for patients and a more efficient workflow for surgeons.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions. The Gelrin platform technology, based on synchronized, degradable hydrogel implants, is initially focused on orthopedic treatments, including inflamed cartilage and bone repair. The lead product GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
For more information, a full corporate profile is available at https://ibn.fm/bpPp6. Forward-looking statements in this release involve risks and uncertainties as detailed in the company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The original press release can be viewed at www.newmediawire.com.
